Immunovant, Inc. Cash Flow Statement

Cash Flow Statement Mar2019 Mar2020 Mar2021 Mar2022 Mar2023 Mar2024 Mar2025
Operating Activities
Net Income -28.60M-66.39M-107.43M-156.73M-210.96M-259.34M-413.84M
Depreciation and Depletion 0.01M0.02M0.07M0.13M0.19M0.23M0.38M
Share-based Compensation 1.31M6.96M18.82M34.24M32.30M41.12M49.49M
Gains from Investment Securities -0.01M4.21M0.13M0.09M7.74M
Asset Writedowns and Impairment 1.63M
Cash from Operations -28.55M-53.36M-83.33M-106.11M-188.19M-214.23M-375.87M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.93M1.11M1.13M1.13M0.13M
Depreciation & Amortization (CF) 0.01M0.02M0.07M0.13M0.19M0.23M0.38M
Change in Working Capital
Change in Receivables 0.60M11.63M-11.76M4.58M-3.23M
Change in Account Payables -0.93M0.97M1.25M16.25M-17.12M5.78M10.68M
Change in Accured Expenses 4.91M6.50M4.47M9.47M15.57M1.35M8.92M
Change in Taxes 0.05M-0.01M0.51M0.09M-0.46M-0.02M0.26M
Investing Activities
Capital Expenditures 0.05M0.03M0.21M0.25M0.20M0.36M0.76M
Cash from Investing Activities -0.05M-0.03M-0.21M-0.25M-0.20M-0.36M-0.76M
Financing Activities
Other financing activities 5.06M3.11M1.24M0.27M6.01M0.32M
Debt Issuance and Repayment
Long-Term Debt Issuances 35.00M
Long-Term Debt Repayments 2.50M3.19M
Change in Capital Stock
Shares Issued 16.13M1.16M1.10M0.13M0.66M5.69M4.81M
Misc.
Cash from Financing Activities 35.58M146.97M383.11M200.13M70.89M472.43M454.49M
Exchange Rate Effect -0.09M0.22M0.99M0.75M
Change in Cash 6.99M93.59M299.57M93.67M-117.28M258.83M78.61M
Free Cash Flow -28.60M-53.39M-83.54M-106.37M-188.39M-214.59M-376.63M
Net Cash Flow 6.99M93.59M299.57M93.76M-117.50M257.84M77.86M